RS BioTherapeutics Appoints Pharmaceutical Industry Veteran Dean Hart as Chief Executive Officer
April 10, 2023 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Selects Recipharm as Product Characterization Partner
November 14, 2022 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
September 26, 2022 09:34 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Appoints Jeremy Plumb as Chief Cultivation Officer
August 01, 2022 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound
July 11, 2022 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., July 11, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound
May 23, 2022 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., May 23, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system to research, develop and...